Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker DRTS · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma NCT06910306 · Recurrent Glioblastoma, Recurrent Gliomas Device :DaRT seeds | DRTS Alpha Tau Medical Ltd. | Not applicable | Recruiting | 20 | Nov 1, 2026 | Registry ↗ |
| Oct 27, 2026 | Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metasta… NCT06698458 · Pancreatic Cancer, Pancreatic Adenocarcinoma Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) | DRTS Alpha Tau Medical Ltd. | Not applicable | Active, not recruiting | 50 | Oct 2026 | Registry ↗ |
| Jul 15, 2026 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Pat… NCT06615635 · Squamous Cell Carcinoma, Alpha Radiation DaRT seeds | DRTS Alpha Tau Medical Ltd. | Not applicable | Recruiting | 28 | Dec 2026 | Registry ↗ |
| Jun 24, 2026 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer NCT06755359 · Pancreatic Cancer, Locally Advanced Pancreatic Cancer Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) | DRTS Alpha Tau Medical Ltd. | Not applicable | Recruiting | 40 | Jan 2027 | Registry ↗ |
| Jun 16, 2026 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prosta… NCT06202248 · Non-metastatic Prostate Cancer, Locally Recurrent Prostate… Experimental: DaRT seeds | DRTS Alpha Tau Medical Ltd. | Not applicable | Recruiting | 10 | Jun 2027 | Registry ↗ |
| Jun 16, 2026 | Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanc… NCT06026943 · Pancreatic Cancer, Unresectable Pancreatic Cancer DaRT seeds insertion | DRTS Alpha Tau Medical Ltd. | Not applicable | Recruiting | 15 | Jan 2027 | Registry ↗ |
| Jun 16, 2026 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases NCT05829291 · Liver Metastases Diffusing Alpha Radiation Emitters Therapy (DaRT) | DRTS Alpha Tau Medical Ltd. | Not applicable | Recruiting | 10 | Feb 2027 | Registry ↗ |
| Jun 16, 2026 | Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors NCT05781555 · Malignant Tumor Experimental: DaRT seeds | DRTS Alpha Tau Medical Ltd. | Not applicable | Recruiting | 100 | Apr 2027 | Registry ↗ |
| Jun 16, 2026 | Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Sa… NCT05657743 · Pancreatic Cancer, Unresectable Pancreatic Cancer Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) | DRTS Alpha Tau Medical Ltd. | Not applicable | Recruiting | 15 | Nov 2026 | Registry ↗ |
| Jun 16, 2026 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer NCT05632913 · Recurrent Lung Cancer, Lung Cancer Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) | DRTS Alpha Tau Medical Ltd. | Not applicable | Recruiting | 10 | Feb 2027 | Registry ↗ |
| Jun 16, 2026 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carci… NCT05323253 · Recurrent Squamous Cell Carcinoma DaRT seeds | DRTS Alpha Tau Medical Ltd. | Not applicable | Active, not recruiting | 86 | Apr 2027 | Registry ↗ |
| Jun 16, 2026 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft… NCT04534127 · Skin Cancer, Mucosal Neoplasm of Oral Cavity Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) | DRTS Alpha Tau Medical Ltd. | Not applicable | Recruiting | 56 | Jan 1, 2027 | Registry ↗ |
| Jun 16, 2026 | Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors NCT04068155 · Skin Cancer, Cutaneous Tumor DaRT- Diffusing Alpha-emitters Radiation Therapy | DRTS Alpha Tau Medical Ltd. | Not applicable | Recruiting | 80 | Jan 2027 | Registry ↗ |
| Apr 6, 2026 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer NCT07290998 · Prostate Cancer, Recurrent Prostate Cancer Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) | DRTS Alpha Tau Medical Ltd. | Not applicable | Not yet recruiting | 12 | May 2028 | Registry ↗ |
| Apr 6, 2026 | Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment… NCT05047094 · Head and Neck Squamous Cell Carcinoma, Skin Cancer Diffusing Alpha Radiation Emitters Therapy (DaRT), Pembroli… | DRTS Alpha Tau Medical Ltd. | Not applicable | Recruiting | 48 | Dec 2026 | Registry ↗ |
| Apr 6, 2026 | Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue… NCT03737734 · Skin Cancer, Mucosal Neoplasm of Oral Cavity Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) | DRTS Alpha Tau Medical Ltd. | Not applicable | Active, not recruiting | 30 | Dec 2026 | Registry ↗ |
| Dec 8, 2025 | Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue… NCT03886181 · Skin Cancer, Mucosal Neoplasm of Oral Cavity Device: Radiation: Diffusing Alpha Radiation Emitters Thera… | DRTS Alpha Tau Medical Ltd. | Not applicable | Terminated | 2 | Oct 13, 2024 | Registry ↗ |
| Dec 2, 2025 | Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With… NCT04543903 · Prostate Adenocarcinoma Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) | DRTS Alpha Tau Medical Ltd. | Not applicable | Completed | 1 | Oct 1, 2025 | Registry ↗ |
| Dec 2, 2025 | Retreatment With Intratumoral Diffusing Alpha Radiation Emitters NCT04540588 · Skin Cancer, Mucosal Neoplasm of Oral Cavity Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) | DRTS Alpha Tau Medical Ltd. | Not applicable | Completed | 2 | Dec 1, 2025 | Registry ↗ |
| Dec 2, 2025 | Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer NCT04002479 · Pancreatic Cancer, Unresectable Pancreatic Cancer Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) | DRTS Alpha Tau Medical Ltd. | Not applicable | Active, not recruiting | 37 | Oct 2026 | Registry ↗ |
| Dec 2, 2025 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft… NCT03889899 · Skin Cancer, Mucosal Neoplasm of Oral Cavity Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) | DRTS Alpha Tau Medical Ltd. | Not applicable | Recruiting | 30 | Jun 2026 | Registry ↗ |
| Feb 7, 2025 | A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly… NCT06202118 · Breast Cancer, Recurrent Breast Cancer Diffusing Alpha Radiation Emitters Therapy (DaRT) | DRTS Alpha Tau Medical Ltd. | Not applicable | Recruiting | 10 | Jan 2026 | Registry ↗ |
| May 17, 2024 | Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC NCT05065346 · Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcin… Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT | DRTS Alpha Tau Medical Ltd. | Not applicable | Unknown | 79 | Dec 2025 | Registry ↗ |
| Jan 31, 2024 | Alpha Radiation Emitters Device for the Treatment of Primary and Recurrent Squamous Cell Carcinoma… NCT06202339 · Carcinoma of the Vulva, Recurrent Carcinoma of the Vulva DaRT seeds | DRTS Alpha Tau Medical Ltd. | Not applicable | Not yet recruiting | 10 | Apr 2026 | Registry ↗ |
| Jan 18, 2024 | Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With… NCT03970967 · Breast Carcinoma, Metastatic Breast Cancer Device: Radiation: Diffusing Alpha Radiation Emitters Thera… | DRTS Alpha Tau Medical Ltd. | Not applicable | Terminated | 1 | Nov 30, 2023 | Registry ↗ |
| Jun 1, 2022 | A Retrospective Analysis to Evaluate Long Term Outcomes of SCC Patients Previously Treated With Alp… NCT05125354 · Squamous Cell Carcinoma, DaRT Treated Patients | DRTS Alpha Tau Medical Ltd. | — | Completed | 33 | Mar 6, 2022 | Registry ↗ |
| Jun 1, 2022 | Feasibility Trial of Diffusing Alpha-emitter Radiation Therapy (DaRT) for Malignant Skin & Superfic… NCT04377360 · Malignant Skin Tumor, Soft Tissue Tumor, Malignant Diffusing Alpha-emitter Radiation Therapy | DRTS Alpha Tau Medical Ltd. | Not applicable | Completed | 10 | Mar 28, 2022 | Registry ↗ |
| Mar 10, 2021 | Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT) NCT03353077 · Skin Squamous Cell Carcinoma Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) | DRTS Alpha Tau Medical Ltd. | Not applicable | Completed | 28 | Jul 14, 2019 | Registry ↗ |
| Jan 13, 2021 | Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma NCT03015883 · Squamous Cell Carcinoma Diffusing Alpha Radiation Emitters Therapy (DaRT) | DRTS Alpha Tau Medical Ltd. | Not applicable | Completed | 28 | Jun 1, 2019 | Registry ↗ |
29 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:31 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances